O	0	1	A
O	2	12	randomized
O	13	23	controlled
O	24	29	trial
O	30	32	of
B-intervention	33	44	emotionally
I-intervention	45	55	expressive
I-intervention	56	63	writing
O	64	67	for
O	68	73	women
O	74	78	with
O	79	89	metastatic
O	90	96	breast
O	97	103	cancer
O	103	104	.

O	105	107	To
O	108	112	test
O	113	116	the
O	117	124	effects
O	125	127	of
O	128	139	emotionally
O	140	150	expressive
O	151	158	writing
O	159	161	in
O	162	163	a
O	164	174	randomized
O	175	185	controlled
O	186	191	trial
O	192	194	of
B-eligibility	195	205	metastatic
I-eligibility	206	212	breast
I-eligibility	213	219	cancer
I-eligibility	220	228	patients
O	229	232	and
O	233	235	to
O	236	245	determine
O	246	253	whether
O	254	261	effects
O	262	264	of
O	265	268	the
O	269	281	intervention
O	282	288	varied
O	289	291	as
O	292	293	a
O	294	302	function
O	303	305	of
O	306	315	perceived
O	316	322	social
O	323	330	support
O	331	333	or
O	334	338	time
O	339	344	since
O	345	355	metastatic
O	356	365	diagnosis
O	365	366	.

O	367	372	Women
O	373	374	(
O	374	375	N
O	376	377	=
B-total-participants	378	380	62
O	380	381	)
B-eligibility	382	388	living
I-eligibility	389	393	with
I-eligibility	394	399	Stage
I-eligibility	400	402	IV
I-eligibility	403	409	breast
I-eligibility	410	416	cancer
O	417	421	were
O	422	430	randomly
O	431	439	assigned
O	440	442	to
O	443	448	write
O	449	454	about
O	455	461	cancer
O	461	462	-
O	462	469	related
O	470	478	emotions
O	479	480	(
O	480	483	EMO
O	483	484	;
O	485	486	n
O	487	488	=
B-intervention-participants	489	491	31
O	491	492	)
O	493	495	or
O	496	499	the
O	500	505	facts
O	506	508	of
O	509	514	their
O	515	524	diagnosis
O	525	528	and
O	529	538	treatment
O	539	540	(
B-control	540	543	CTL
O	543	544	;
O	545	546	n
O	547	548	=
B-control-participants	549	551	31
O	551	552	)
O	552	553	.

O	554	566	Participants
O	567	572	wrote
O	573	575	at
O	576	580	home
O	581	584	for
O	585	589	four
O	590	592	20
O	592	593	-
O	593	596	min
O	597	605	sessions
O	606	612	within
O	613	614	a
O	615	616	3
O	616	617	-
O	617	621	week
O	622	630	interval
O	630	631	.

O	632	642	Depressive
O	643	651	symptoms
O	651	652	,
O	653	659	cancer
O	659	660	-
O	660	667	related
O	668	677	intrusive
O	678	686	thoughts
O	686	687	,
O	688	695	somatic
O	696	704	symptoms
O	704	705	,
O	706	709	and
O	710	715	sleep
O	716	723	quality
O	724	726	at
O	727	728	3
O	729	735	months
O	736	752	postintervention
O	752	753	.

O	754	756	No
O	757	768	significant
O	769	773	main
O	774	781	effects
O	782	784	of
O	785	797	experimental
O	798	807	condition
O	808	812	were
O	813	821	observed
O	821	822	.

O	823	824	A
B-outcome	825	836	significant
I-outcome	837	846	condition
I-outcome	847	848	x
I-outcome	849	855	social
I-outcome	856	863	support
I-outcome	864	875	interaction
I-outcome	876	883	emerged
I-outcome	884	886	on
I-outcome	887	896	intrusive
I-outcome	897	905	thoughts
O	905	906	;
O	907	910	EMO
O	911	918	writing
O	919	922	was
O	923	933	associated
O	934	938	with
O	939	946	reduced
O	947	956	intrusive
O	957	965	thoughts
O	966	969	for
O	970	975	women
O	976	985	reporting
O	986	989	low
O	990	999	emotional
O	1000	1007	support
O	1008	1009	(
O	1009	1013	eta2
O	1014	1015	=
O	1016	1017	.
O	1017	1019	15
O	1019	1020	)
O	1020	1021	.

B-outcome	1022	1033	Significant
I-outcome	1034	1043	condition
I-outcome	1044	1045	x
I-outcome	1046	1050	time
I-outcome	1051	1056	since
I-outcome	1057	1067	metastatic
I-outcome	1068	1077	diagnosis
I-outcome	1078	1090	interactions
O	1091	1095	were
O	1096	1100	also
O	1101	1109	observed
O	1110	1113	for
O	1114	1121	somatic
O	1122	1130	symptoms
O	1131	1134	and
O	1135	1140	sleep
O	1141	1153	disturbances
O	1153	1154	.

O	1155	1163	Relative
O	1164	1166	to
O	1167	1170	CTL
O	1170	1171	,
O	1172	1175	EMO
O	1176	1188	participants
O	1189	1192	who
O	1193	1197	were
O	1198	1202	more
O	1203	1211	recently
O	1212	1221	diagnosed
O	1222	1225	had
O	1226	1231	fewer
O	1232	1239	somatic
O	1240	1248	symptoms
O	1249	1250	(
O	1250	1254	eta2
O	1255	1256	=
O	1257	1258	.
O	1258	1260	10
O	1260	1261	)
O	1261	1262	,
O	1263	1270	whereas
O	1271	1274	EMO
O	1275	1287	participants
O	1288	1292	with
O	1293	1299	longer
O	1300	1309	diagnosis
O	1310	1318	duration
O	1319	1328	exhibited
B-outcome	1329	1338	increases
I-outcome	1339	1341	in
I-outcome	1342	1347	sleep
I-outcome	1348	1360	disturbances
O	1361	1362	(
O	1362	1366	eta2
O	1367	1368	=
O	1369	1370	.
O	1370	1372	09
O	1372	1373	)
O	1373	1374	.

O	1375	1383	Although
O	1384	1389	there
O	1390	1393	was
O	1394	1396	no
O	1397	1401	main
O	1402	1408	effect
O	1409	1411	of
O	1412	1422	expressive
O	1423	1430	writing
O	1431	1433	on
O	1434	1440	health
O	1441	1446	among
O	1447	1450	the
O	1451	1458	current
O	1459	1469	metastatic
O	1470	1476	breast
O	1477	1483	cancer
O	1484	1490	sample
O	1490	1491	,
O	1492	1502	expressive
O	1503	1510	writing
O	1511	1514	may
O	1515	1517	be
O	1518	1528	beneficial
O	1529	1532	for
O	1533	1534	a
O	1535	1541	subset
O	1542	1544	of
O	1545	1555	metastatic
O	1556	1564	patients
O	1565	1566	(
O	1566	1575	including
O	1576	1581	women
O	1582	1586	with
O	1587	1590	low
O	1591	1597	levels
O	1598	1600	of
O	1601	1610	emotional
O	1611	1618	support
O	1619	1621	or
O	1622	1625	who
O	1626	1630	have
O	1631	1635	been
O	1636	1644	recently
O	1645	1654	diagnosed
O	1654	1655	)
O	1656	1659	and
O	1660	1675	contraindicated
O	1676	1679	for
O	1680	1686	others
O	1687	1688	(
O	1688	1689	i
O	1689	1690	.
O	1690	1691	e
O	1691	1692	.
O	1692	1693	,
O	1694	1699	those
O	1700	1703	who
O	1704	1708	have
O	1709	1713	been
O	1714	1720	living
O	1721	1725	with
O	1726	1729	the
O	1730	1739	diagnosis
O	1740	1743	for
O	1744	1749	years
O	1749	1750	)
O	1750	1751	.
